Tags

Type your tag names separated by a space and hit enter

Rhenium-Based Complexes and in Vivo Testing: A Brief History.
Chembiochem. 2020 Aug 03; 21(15):2111-2115.C

Abstract

The success of metal-based anticancer therapeutics in the treatment of cancer is best exemplified by cisplatin. Currently used in 32/78 cancer regimens, metal-based drugs have a clear role in cancer therapy. Despite this, metal-based anticancer therapeutics are not without drawbacks, with issues such as toxic side effects and the development of resistance mechanisms. This has led to investigations of other metal-based drug candidates such as auranofin, a gold-based drug candidate as well as ruthenium-based candidates, NAMI-A, NKP-1339 and TLD-1433. All are currently undergoing clinical trials. Another class of complexes under study are rhenium-based; such complexes have undergone extensive in vitro testing but only nine have been reported to display antitumour in vivo activity, which is a necessary step before entering clinical trials. This review will document, chronologically, the rhenium-based drug candidates that have undergone in vivo testing and the outlook for such complexes.

Authors+Show Affiliations

Department of Earth Science and Engineering, Imperial College London, Royal School of Mines, Prince Consort Rd, Kensington London, SW7 2AZ, UK.Department of Earth Science and Engineering, Imperial College London, Royal School of Mines, Prince Consort Rd, Kensington London, SW7 2AZ, UK.Department of Earth Science and Engineering, Imperial College London, Royal School of Mines, Prince Consort Rd, Kensington London, SW7 2AZ, UK.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32196894

Citation

Capper, Miles S., et al. "Rhenium-Based Complexes and in Vivo Testing: a Brief History." Chembiochem : a European Journal of Chemical Biology, vol. 21, no. 15, 2020, pp. 2111-2115.
Capper MS, Packman H, Rehkämper M. Rhenium-Based Complexes and in Vivo Testing: A Brief History. Chembiochem. 2020;21(15):2111-2115.
Capper, M. S., Packman, H., & Rehkämper, M. (2020). Rhenium-Based Complexes and in Vivo Testing: A Brief History. Chembiochem : a European Journal of Chemical Biology, 21(15), 2111-2115. https://doi.org/10.1002/cbic.202000117
Capper MS, Packman H, Rehkämper M. Rhenium-Based Complexes and in Vivo Testing: a Brief History. Chembiochem. 2020 Aug 3;21(15):2111-2115. PubMed PMID: 32196894.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rhenium-Based Complexes and in Vivo Testing: A Brief History. AU - Capper,Miles S, AU - Packman,Hollie, AU - Rehkämper,Mark, Y1 - 2020/04/14/ PY - 2020/02/27/received PY - 2020/03/19/revised PY - 2020/3/21/pubmed PY - 2020/3/21/medline PY - 2020/3/21/entrez KW - Antitumor KW - chemotherapy KW - cisplatin KW - in vivo KW - rhenium SP - 2111 EP - 2115 JF - Chembiochem : a European journal of chemical biology JO - Chembiochem VL - 21 IS - 15 N2 - The success of metal-based anticancer therapeutics in the treatment of cancer is best exemplified by cisplatin. Currently used in 32/78 cancer regimens, metal-based drugs have a clear role in cancer therapy. Despite this, metal-based anticancer therapeutics are not without drawbacks, with issues such as toxic side effects and the development of resistance mechanisms. This has led to investigations of other metal-based drug candidates such as auranofin, a gold-based drug candidate as well as ruthenium-based candidates, NAMI-A, NKP-1339 and TLD-1433. All are currently undergoing clinical trials. Another class of complexes under study are rhenium-based; such complexes have undergone extensive in vitro testing but only nine have been reported to display antitumour in vivo activity, which is a necessary step before entering clinical trials. This review will document, chronologically, the rhenium-based drug candidates that have undergone in vivo testing and the outlook for such complexes. SN - 1439-7633 UR - https://www.unboundmedicine.com/medline/citation/32196894/Rhenium-Based_Complexes_and_in_Vivo_Testing:_A_Brief_History L2 - https://doi.org/10.1002/cbic.202000117 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.